首页> 外文期刊>Pharmaceutical statistics. >Resampling-based stepwise multiple testing procedures with applications to clinical trial data
【24h】

Resampling-based stepwise multiple testing procedures with applications to clinical trial data

机译:基于重采样的逐步多次测试程序,其中包含临床试验数据

获取原文
获取原文并翻译 | 示例
       

摘要

Endpoints in clinical trials are often highly correlated. However, the commonly used multiple testing procedures in clinical trials either do not take into consideration the correlations among test statistics or can only exploit known correlations. Westfall and Young constructed a resampling-based stepdown method that implicitly utilizes the correlation structure of test statistics in situations with unknown correlations. However, their method requires a "subset pivotality" assumption. Romano and Wolf proposed a more general stepdown method, which does not require such an assumption. There is at present little experience with the application of such methods in analyzing clinical trial data. We advocate the application of resampling-based multiple testing procedures to clinical trials data when appropriate. We have conjectured that the resampling-based stepdown methods can be extended to a stepup procedure under appropriate assumptions and examined the performance of both stepdown and stepup methods under a variety of correlation structures and distribution types. Results from our simulation studies support the use of the resampling-based methods under various scenarios, including binary data and small samples, with strong control of Family wise type I error rate (FWER). Under positive dependence and for binary data even under independence, the resampling-based methods are more powerful than the Holm and Hochberg methods. Last, we illustrate the advantage of the resampling-based stepwise methods with two clinical trial data examples: a cardiovascular outcome trial and an oncology trial.
机译:临床试验的终点通常高度相关。然而,临床试验中常用的多种测试程序要么没有考虑测试统计数据之间的相关性,要么只能利用已知的相关性。Westfall和Young构建了一种基于重采样的逐步下降方法,在相关性未知的情况下隐式地利用了测试统计的相关结构。然而,他们的方法需要“子集枢轴性”假设。Romano和Wolf提出了一种更通用的降压方法,它不需要这样的假设。目前,在分析临床试验数据时应用这些方法的经验很少。我们提倡在适当的时候对临床试验数据应用基于重采样的多重检测程序。我们推测,在适当的假设下,基于重采样的逐步下降方法可以扩展到逐步上升过程,并在各种相关结构和分布类型下检验了逐步下降和逐步上升方法的性能。我们的模拟研究结果支持在各种情况下使用基于重采样的方法,包括二进制数据和小样本,并能很好地控制I型错误率(FWER)。在正相关条件下,即使在独立条件下,基于重采样的方法也比Holm和Hochberg方法更有效。最后,我们用两个临床试验数据例子来说明基于重采样的逐步方法的优势:心血管结局试验和肿瘤学试验。

著录项

  • 来源
    《Pharmaceutical statistics.》 |2021年第2期|共17页
  • 作者单位

    US FDA Div Biometr 2 Off Biostat Off Translat Sci Ctr Drug Evaluat &

    Res Silver Spring MD;

    US FDA Div Biometr 2 Off Biostat Off Translat Sci Ctr Drug Evaluat &

    Res Silver Spring MD;

    Univ Illinois Dept Epidemiol &

    Biostat Chicago IL USA;

    US FDA Div Biometr 2 Off Biostat Off Translat Sci Ctr Drug Evaluat &

    Res Silver Spring MD;

  • 收录信息
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类 药学;
  • 关键词

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号